ArticleVaccine2007
MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Tumor glycosylation engages CD301b-mediated myeloid regulation in breast cancer.Research square · 2026Article
- CD301b lectin expression in the breast tumor microenvironment augments tumor growth.Research square · 2025Article
- CD301b lectin expression in the breast tumor microenvironment augments tumor growth.bioRxiv : the preprint server for biology · 2025Article
- Dual-functional probe for sensitive detection of MCF-7 cells and mendelian randomization analysis of MUC1 association with multiple cancers.Scientific reports · 2025Article
- Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer.Discover oncology · 2024Review
- The Role of MUC1 in Renal Cell Carcinoma.Biomolecules · 2024Review
- Vaccination and Microbiota Manipulation Approaches for Colon Cancer Prevention in Rodent Models.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Prevention of Inflammation-Driven Colon Carcinogenesis in Human MUC1 Transgenic Mice by Vaccination withCancers · 2023Article
- Review
- Review
- A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer.Current topics in medicinal chemistry · 2022Review
- Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.World journal of gastrointestinal surgery · 2021Review
- Cancer Immunoprevention: Current Status and Future Directions.Archivum immunologiae et therapiae experimentalis · 2021Review
- uMUC1-Targeting Magnetic Resonance Imaging of Therapeutic Response in an Orthotropic Mouse Model of Colon Cancer.Molecular imaging and biology · 2019Article
- Article
- Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.PloS one · 2019Article
- Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.Frontiers in immunology · 2019Article
- Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
A MUC1-based vaccine was used in a preclinical model of colon cancer. The trial was conducted in a MUC1-tolerant immune competent host injected with MC38 colon cancer cells expressing MUC1. The vaccine included: MHC class I-restricted MUC1 peptides, MHC class II-restricted pan-helper-peptide, unmethylated CpG oligodeoxynucleotide, and granulocyte macrophage-colony stimulating factor. Immunization was successful in breaking MUC1 self-tolerance, and in eliciting a robust anti-tumor response. The vaccine stimulated IFN-gamma-producing CD4(+) helper and CD8(+) cytotoxic T cells against MUC1 and other undefined MC38 tumor antigens. In the prophylactic setting, immunization caused complete rejection of tumor cells, while in the therapeutic regimen, tumor burden was significantly reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.